452 related articles for article (PubMed ID: 10771451)
1. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.
Everson G; Lasseter KC; Anderson KE; Bauer LA; Carithens RL; Wilner KD; Johnson A; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):21S-26S. PubMed ID: 10771450
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers.
Wilner KD; Tensfeldt TG; Baris B; Smolarek TA; Turncliff RZ; Colburn WA; Hansen RA
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):15S-20S. PubMed ID: 10771449
[TBL] [Abstract][Full Text] [Related]
4. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.
Miceli JJ; Anziano RJ; Robarge L; Hansen RA; Laurent A
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):65S-70S. PubMed ID: 10771457
[TBL] [Abstract][Full Text] [Related]
5. The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.
Miceli JJ; Smith M; Robarge L; Morse T; Laurent A
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):71S-76S. PubMed ID: 10771458
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of pioglitazone in patients with impaired renal function.
Budde K; Neumayer HH; Fritsche L; Sulowicz W; Stompôr T; Eckland D
Br J Clin Pharmacol; 2003 Apr; 55(4):368-74. PubMed ID: 12680885
[TBL] [Abstract][Full Text] [Related]
7. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
8. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
9. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.
Miceli JJ; Wilner KD; Hansen RA; Johnson AC; Apseloff G; Gerber N
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):5S-13S. PubMed ID: 10771448
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone and the pharmacokinetics of a combined oral contraceptive.
Muirhead GJ; Harness J; Holt PR; Oliver S; Anziano RJ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):49S-56S. PubMed ID: 10771454
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid.
Wilner KD; Hansen RA; Folger CJ; Geoffroy P
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):57S-60S. PubMed ID: 10771455
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.
Miceli JJ; Wilner KD; Swan SK; Tensfeldt TG
J Clin Pharmacol; 2005 Jun; 45(6):620-30. PubMed ID: 15901743
[TBL] [Abstract][Full Text] [Related]
13. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.
Mazzu AL; Lettieri JT; Kelly E; Vargas R; Marbury T; Liu MC; Sundaresan P
Eur J Clin Pharmacol; 2000 Apr; 56(1):69-74. PubMed ID: 10853881
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.
Chapelsky MC; Thompson-Culkin K; Miller AK; Sack M; Blum R; Freed MI
J Clin Pharmacol; 2003 Mar; 43(3):252-9. PubMed ID: 12638393
[TBL] [Abstract][Full Text] [Related]
18. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
19. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
Sobue S; Tan K; Layton G; Leclerc V; Weil A
Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
[TBL] [Abstract][Full Text] [Related]
20. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.
O'Grady P; Yee KF; Lins R; Mangold B
Br J Clin Pharmacol; 1999 Sep; 48(3):375-81. PubMed ID: 10510149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
